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Abstract
Japanese encephalitis virus (JEV), a neurotropic mosquito-borne flavivirus, causes acute viral encephalitis and neurologic
disease with a high fatality rate in humans and a range of animals. Small interfering RNA (siRNA) is a powerful antiviral agent
able to inhibit JEV replication. However, the high rate of genetic variability between JEV strains (of four confirmed
genotypes, genotypes I, II, III and IV) hampers the broad-spectrum application of siRNAs, and mutations within the targeted
sequences could facilitate JEV escape from RNA interference (RNAi)-mediated antiviral therapy. To improve the broad-
spectrum application of siRNAs and prevent the generation of escape mutants, multiple siRNAs targeting conserved viral
sequences need to be combined. In this study, using a siRNA expression vector based on the miR-155 backbone and
promoted by RNA polymerase II, we initially identified nine siRNAs targeting highly conserved regions of seven JEV genes
among strains of the four genotypes of JEV to effectively block the replication of the JEV vaccine strain SA14-14-2. Then, we
constructed single microRNA-like polycistrons to simultaneously express these effective siRNAs under a single RNA
polymerase II promoter. Finally, these single siRNAs or multiple siRNAs from the microRNA-like polycistrons showed
effective anti-virus activity in genotype I and genotype III JEV wild type strains, which are the predominant genotypes of JEV
in mainland China. The anti-JEV effect of these microRNA-like polycistrons was also predicted in other genotypes of JEV
(genotypes II and IV), The inhibitory efficacy indicated that siRNAs69 could theoretically inhibit the replication of JEV
genotypes II and IV.
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Introduction
Japanese encephalitis virus (JEV), a neurotropic mosquito-borne
flavivirus mainly prevalent in Asia, is the most important causative
agent of acute viral encephalitis in humans [1]. It is estimated that
JEV is responsible for at least 50,000 cases of viral encephalitis
worldwide each year, resulting in 10,000–15,000 deaths and
15,000 cases with long-term, neuropsychiatric sequelae [2]. JEV is
also one of the main causes of infectious reproductive failure in
swine, resulting in significant economic losses in the pig industry.
This virus has a normal zoonotic transmission cycle between swine
or birds and mosquitoes. Swine are the main amplifier hosts, from
which infected mosquitoes transmit the virus to humans [3].
Currently, a live attenuated JEV vaccine, SA 14-14-2, with
excellent immunogenicity, is widely used in humans in China and
other countries in Asia [2,4]. Although great success has been
achieved with this vaccine, there is still no specific therapy
available for ongoing JEV infection in humans.
JEV is a member of the genus Flavivirus, part of the family
Flaviviridae. The JEV genome is a positive single-stranded RNA
molecule of about 11 kb in length. It contains a single open
reading frame encoding a polyprotein that is flanked by 59- and 39-
untranslated regions (UTRs). The polyprotein is co-translationally
and post-translationally cleaved by the virus-encoded serine
protease, NS2B/NS3, and by host-encoded proteases to produce
three structural proteins (C, prM and E) and seven nonstructural
proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) [5,6,7].
Based on the nucleotide sequences of the C/PrM and E genes,
JEV isolates have been classified into four genotypes (genotypes I,
II, III and IV) and a postulated fifth genotype (Muar strain).
Genotypes I and III are associated with epidemic regions in China,
Korea, Japan, India, Thailand, the Philippines and other countries
in Asia, whereas, genotypes II and IV are associated with endemic
disease in Malaysia, Indonesia and northern Australia
[8,9,10,11,12]. Among these, genotype III has the widest
geographic distribution in Asia, and the vaccine strain, SA 14-
14-2, is derived from wild type strain SA14 of genotype III.
RNA interference (RNAi), a mechanism widely present in
eukaryotes, is an evolutionarily conserved process of sequence-
specific gene silence initiated by double-stranded RNAs (dsRNAs)
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26304or microRNAs (miRNAs) [13]. In the case of dsRNAs, the dsRNAs
are cleaved by Dicer (a host ribonuclease-III like enzyme) into 21–
25 nt small interfering RNAs (siRNAs). These siRNAs are
incorporated into a multi-protein complex known as ‘‘RNA-
induced silencing complex’’ (RISC) in the cytoplasm and direct
RISC to degrade homologous target mRNAs [14,15]. In the case of
miRNAs,theprimaryRNAtranscripts(pri-miRNAs)arecleaved by
Drosha into 60–70 nt miRNA precursors (pre-miRNAs) in the
nucleus. Pre-miRNAs are transported into the cytoplasm by
Exportin-5 and then cleaved into ,22 nt miRNAs by Dicer. The
mature miRNAs are incorporated into RISC and direct RISC to
cleave mRNA or repress translation. Most pri-miRNA transcripts
encode clusters of distinct miRNAs under the control of a single
RNA polymerase II promoter [13,16]. In mammalian cells, an
RNAi effect can be induced by introducing either exogenous
synthetic 21–29 nt siRNAs or RNA polymerase III-driven short-
hairpin RNA (shRNA) vectors [17,18,19,20].
In the past decade, RNAi has been used successfully for clearing
mammalian cells of various viral infections [21,22,23,24]. For JEV,
a potent inhibitory effect has been reported with single siRNA or
shRNA [3,25,26,27]. However, because of the genetic variability of
JEV [10,11] and escape mutations in the targeted sequences [28],
the therapeutic application of single siRNA or shRNA is limited.
Therefore, multiple siRNAs targeting conserved viral sequences
need to be combined in this case. Recently, a new miRNA-like
siRNA expression platform based on miRNA principles has been
reported in many studies. These siRNAs are expressed from the pri-
miRNA backbone by constructing heterologous siRNAs into pri-
miRNA hairpin stems under the control of a RNA polymerase II.
Like most miRNAs that are transcribed from polycistronic pri-
miRNAs, multiple siRNAs can be synthesized from a single
polycistronic transcript using this strategy [22,29,30,31,32,33]. This
platform allows us to simultaneously transcribe to similar levels
multiple, effective siRNAs against JEV from a single promoter-
driven miRNA-like polycistronic construct.
In this study, we initially analyzed the molecular epidemiolog-
ical characteristics of JEV, and determined the highly conserved
sequences of eight JEV genes (PrM, NS1, NS2A, NS2B, NS3,
NS4A, NS4B and NS5) among the four genotypes. Thirteen
siRNAs against the selected conserved regions of these genes were
designed and constructed individually into a RNA polymerase II-
driven siRNA expression vector based on the miR-155 backbone.
Using a siRNA-to-target reporter assay system [34,35], nine
effective siRNAs out of the 13 tested were selected to investigate
their inhibitory effects on JEV replication in cultured cells. Then,
these nine siRNA cassettes were combined in different sequences
using the polycistronic nature of the miRNAs. The results showed
that either a single siRNA or multiple siRNAs of these nine
siRNAs could inhibit the replication of the genotype III strain, the
live attenuated vaccine strain SA14-14-2. Finally, three wild type
strains (SH53, SH101 and SA14) of genotypes I and III, which are
predominant in mainland China, were chosen to validate the anti-
JEV effect of these multiple siRNAs from miRNA-like polycis-
trons. The replication of the three wild type strains was inhibited
effectively by these miRNA-like polycistrons. Furthermore, the
anti-JEV effect of these miRNA-like polycistrons was predicted in
genotypes II and IV, and the effect of a few nucleotide mismatches
within the target regions was also estimated.
Results
Design and selection of siRNAs against JEV
Sixty-four JEV genome sequences of the four genotypes
available in GenBank (including 34 Chinese strains) were aligned
using the SeqMan program. siRNAs against the eight selected
genes were obtained using the miRNA design algorithm from
Invitrogen. Thirteen siRNAs whose targets showed $95%
conservation among the 34 Chinese strains and $80% conserva-
tion among the 64 strains (Figure 1 and Table 1) were selected and
cloned into pcDNA 6.2–GW/EmGFP-miR according to the
manufacturer’s recommendations (the sequences of hairpin siRNA
inserts were shown in Table S1). As genotypes I and III are the
predominant genotypes in the Chinese mainland [11], these 13
selected siRNA targets were highly conserved in genotypes I and
III and reasonably well conserved in genotypes II and IV. Thus
the 13 selected siRNAs were designed to be fully complementary
to the viral RNA of genotypes I and III, and somewhat imperfectly
complementary to the viral RNA of genotypes II and IV.
The siRNA-encoding pcDNA 6.2–GW/EmGFP-miR vectors
or the negative control (NC) were co-transfected together with the
corresponding siQuant vectors into Baby hamster kidney cell line
(BHK-21; ATCC, USA) cells. Using the Dual-Luciferase Reporter
Assay system, we selected nine out of 13 siRNAs that could
knockdown the expression of the corresponding targets by greater
than 80% compared with the mock control (transfected subcloned
siQuant vector without the siRNA-encoding pcDNA 6.2–GW/
EmGFP-miR vectors) and the NC (P,0.01) (Figure 2).
Comparison of the inhibitory effect on target expression
between single siRNAs and combinations of multiple
siRNAs from single miRNA-like polycistrons
Using the clone strategy described in the Materials and Methods
section, we obtained six miRNA-like polycistron constructs expressing
different combinations of siRNAs (Figure 3A). NS1-447, the most
effective siRNA, was multiplied to generate (NS1-447)63, (NS1-
447)66, and (NS1-447)69. siRNAs64 were constructed from four of
Figure 1. Schematic representations of the JEV RNA structure and the siRNA target sites. Thirteen target sites are indicated and labeled
with the name of the corresponding siRNA.
doi:10.1371/journal.pone.0026304.g001
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siRNAs65 were formed from the other five siRNAs (NS2A-461,
NS2B-123, NS3-1112, NS4A-289, and NS4B-115). All nine of the
siRNAs were constructed into a chain to generate siRNAs69.
The miRNA-like polycistron vectors or the NC were co-
transfected together with the corresponding siQuant vectors into
BHK-21 cells. Using the Dual-Luciferase Reporter Assay system,
the inhibitory effects of miRNA-like polycistrons on the expression
of each target were compared with single siRNAs (Figure 3B, 3C).
Figure 3B showed that the expression of each target could also be
inhibited efficiently by miRNA-like polycistrons (siRNAs64,
siRNAs65, and siRNAs69). Although the inhibitory efficacy of
each siRNA fluctuated when chained as polycistrons, the efficacies
ofmostsiRNAscouldalsomaintainahighlevel,andtheefficaciesof
some siRNAs were even enhanced when chained in polycistrons. As
shown in Figure 3C, as the number of copies of NS1-447 increased
from 1 to 3 to 6 to 9, the expression of its target decreased from
7.1% to 4.3% to 4.0% to 4.2%, respectively, compared with the
mock control (P,0.01). The efficacy of NS1-447 expressed from
siRNAs64 and siRNAs69 was similar to that of the single copy of
NS1-447. As a negative control, siRNA65 could not inhibit the
expression of the target because it did not contain NS1-447.
Inhibitory effects on JEV strain SA 14-14-2 replication of
the transient transfection of single siRNAs or
combinations of multiple siRNAs from single miRNA-like
polycistrons
To test if the nine selected siRNAs or miRNA-like polycistrons
could inhibitefficiently the replication of JEVininfected cells,BHK-
21 cells were challenged with JEV strain SA 14-14-2 at a MOI of 0.1
after being transiently transfected with siRNA-encoding pcDNA
6.2–GW/EmGFP-miR vectors for 24 h. The inhibitory effects of
siRNAs on JEV replication were analyzed at the RNA and protein
levels by real-time RT-PCR and western blot analysis. Twenty-four
hours post-infection, viral RNA copies in cultured cells were
determined by real-time RT-PCR from each well. The copy
number of virus RNA from siRNA-transfected cells dropped to
55.5%–77.1% compared with the mock control (non-transfected
BHK-21 cells) (P,0.05) (Figure 4A). NS1-447 was the most effective
single siRNA, and siRNAs69 was the most effective miRNA-like
polycistron. Twenty-four hours post-infection, the E (envelope)
protein of JEV expressed in BHK-21 cells was detected by mouse
anti-JEV E-D3 monoclonal antibody,and actinproteinwasdetected
as an internal control. E protein expression in siRNA-transfected
cells reduced to 29.2%–46.6% compared with the mock control
(Figure 4B). Similarly, NS1-447 was the most effective single siRNA,
and siRNAs69 was the most effective miRNA-like polycistron.
To analyze the transfection efficiency of the siRNA-encoding
pcDNA 6.2–GW/EmGFP-miR vector transiently transfected by
Lipofectamine 2000, the single siRNA-encoding pcDNA 6.2–GW/
EmGFP-miR transfected BHK-21 cells were assayed by flow
cytometry to calculate the percentage of EmGFP positive cells. As
shown in Figure S1, only 32.9%of the cellswere EmGFP positive. This
Table 1. Target sequences of the siRNAs.
siRNA name Target sequence (all sequences are from 59 to 39)
PrM-54 CATTGCAGACGTTATCGTGAT
NS1-447 TTGGAACAGCATGCAAATCGA
NS1-473 TCGGCTTTGGCATCACATCAA
NS1-630 GAAACTTGAGAGGGCAGTCTT
NS1-1207 TACACTGATTTGGCGAGGTAT
NS2A-193 ATCCTGAATGCCGCCGCTATA
NS2A-461 GACTAATGGTCTGCAACCCAA
NS2B-123 GTCCTACGTGGTGTCAGGAAA
NS3-1112 AGATTGCAATGTGCCTCCAAA
NS3-1469 CAGAGGCAAAGATCATGTTAG
NS4A-289 GCAGAGGTTCCTGGAACCAAA
NS4B-115 ACTGATGTGCCTGAACTGGAA
NS5-741 AGTGTGGAGAGGGCCAAAGTA
NC GTTTCCGAGGCCATAAGTATT
doi:10.1371/journal.pone.0026304.t001
Figure 2. siRNA efficacy validation. BHK-21 cells were transfected with 400 ng of siRNA-encoding pcDNA 6.2–GW/EmGFP-miR vector, 170 ng of
the corresponding siQuant reporter vector and 17 ng of internal control vector pRL-TK. Cells were harvested 48 hours post-transfection, and the
luciferase activities were detected. Data represent the average values from triplicate experiments.
doi:10.1371/journal.pone.0026304.g002
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efficacy of our siRNA constructs, and that reasonable anti-JEV effects
c o u l db eo b t a i n e de v e na tl o ws i R N At r a n s f e c t i o ne f f i c i e n c i e s .
Inhibitory effects on JEV strain SA 14-14-2 replication by
stable cell lines constitutively expressing siRNAs
To minimize the variables associated with transient transfec-
tion, we constructed four stable cell lines constitutively expressing
NS1-447, (NS1-447)66, siRNAs69, and the NC. NS1-447 was the
most effective single siRNA, (NS1-447)66 was the hexamer of NS1-
447 and siRNAs69 was the most effective polycistron of all nine
siRNAs.
The four stable cell lines or normal BHK-21 cells were seeded in
24-well or 96-well plates at equal cell numbers. When the cell layer
reached 90–100% confluence, the cells were infected with JEV
strain SA 14-14-2 at a MOI of 0.1. Twenty-four hours post-
infection, viral RNA copies in cultured cells were determined by
Figure 3. Comparison of the inhibitory effect on target expression between single siRNAs and miRNA-like polycistrons. (A) Schematic
representations of the pcDNA 6.2–GW/EmGFP-miR vectors expressing different combinations of siRNA cassettes. (B) 400 ng of siRNAs64, siRNAs65
or siRNAs69 was co-transfected into BHK-21 cells along with 170 ng of each of the corresponding siQuant reporters and 17 ng of the internal control
pRL-TK. Cells were harvested 48 hours post-transfection and the luciferase activities were detected. (C) 400 ng of NS1-447, (NS1-447)63, (NS1-447)66,
(NS1-447)69, siRNAs64, siRNAs65 or siRNAs69 was co-transfected into BHK-21 cells along with 170 ng of each of the corresponding siQuant
reporters and 17 ng of the internal control pRL-TK. Cells were harvested 48 hours post-transfection and the luciferase activities were detected. Data
represent the average values from triplicate experiments.
doi:10.1371/journal.pone.0026304.g003
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RNA from stable lines constitutively expressing siRNAs69, (NS1-
447)66 and NS1-447 dropped significantly to 15.1%, 3.9% and
21.8%, respectively, compared with the mock control (infected
BHK-21 cells) (P,0.01) (Figure 5A). Thirty-six hours post-
infection, E protein expression was determined by western blot
analysis. E protein expression in stable cell lines constitutively
expressing siRNAs69, (NS1-447)66 and NS1-447 was signifi-
cantly reduced compared with the mock control and the NC
(Figure 5B). Forty-eight hours post-infection, viral titers in the
culture supernatants were examined for each well. Viral titers
from stable cell lines dropped significantly to 5–6.32 TCID50/
0.1 ml, compared with a viral titer in the mock control of 8.75
TCID50/0.1 ml (P,0.01) (Figure 5C). Ninety-six hours post-
infection, the morphological changes in the stable cell lines were
examined by phase-contrast microscopy, and cell viability assays
were performed to analyze the proliferation conditions of each
stable cell line. In the stable cell lines constitutively expressing
siRNAs69, (NS1-447)66 and NS1-447, most cells were alive
compared with the cell control (non-infected BHK-21 cells), and
approximately 95% of cells were killed in the mock control and
the NC (P,0.01) (Figure 5D and Figure S2). The results of viral
RNA and E protein analysis, and the results of viral titer and cell
viability assays, indicated that (NS1-447)66 and siRNAs69w e r e
the two most effective agents at inhibiting the replication of JEV
strain SA 14-14-2.
Comparison of the inhibitory effects of miRNA-like
polycistrons on genotypes I and III of JEV
To test if the miRNA-like polycistrons, (NS1-447)66a n d
siRNAs69, that were shown to inhibit the live attenuated vaccine
strain SA14-14-2, could also inhibit the replication of the two major
epidemic genotypes of JEV (genotypes I and III), three wild type
strains (SH53, SH101 and SA14) of genotypes I and III, which are
predominant in the Chinese mainland, were used to infect cells
c o n t a i n i n gt h et w om i c r o R N A - l i k ep o l y c i s t r o n s .T h en i n es e l e c t e d
siRNAswere designedto befullycomplementaryto the viralRNA of
genotypes I and III because all target sequences of the nine selected
siRNAs were extremely conserved in genotypes I and III.
The four stable cell lines or normal BHK-21 cells were seeded in
24-well or 96-well plates. When the cell layer reached 90–100%
confluence, the cells were infected with JEV strains SA 14, SH53 or
SH101 at a MOI of 0.1. Thirty-six hours post-infection, E protein
expression was detected by western blot analysis. Compared with the
mock control and the NC, E protein expression from each of the
strains (SA14, SH53 and SH101) was significantly inhibited in the
stably trasfected cell lines constitutively expressing (NS1-447)66a n d
siRNAs69 (Figure 6A, 6B, 6C). Forty-eight hours post-infection, viral
titers in the culture supernatants were examined. The viral titers of
SA14, SH53 and SH101 dropped drastically compared with the mock
control and the NC (Figure 6D). Ninety-six hours post-infection, cell
viability assays were performed to analyze the proliferation ability of
the stable cell lines. In the (NS1-447)66a n ds i R N A s 69 stably-
expressing cell lines, most of the cells infected with SA14, SH53, and
SH101 were alive compared with the mock control and the NC, in
which over 80% of cells were killed (Figure 6E). The results of viral E
protein analysis, viral titers and cell viability assays indicated that
(NS1-447)66a n ds i R N A s 69 were also effective against the two major
epidemic genotypes of JEV, genotypes I and III.
Prediction of the inhibitory efficacy of miRNA-like
polycistrons on genotype II and genotype IV of JEV
To confirm that siRNAs69 that inhibited the replication of JEV
genotypes I and III could also inhibit the replication of the two
endemic genotypes of JEV (genotypes II and IV), the target
Figure 4. Inhibitory effects on JEV strain SA 14-14-2 replication by transient transfection of siRNA-encoding vectors. Cells seeded in
24-well plates were transfected with 800 ng of single siRNAs or miRNA-like polycistrons. Twenty-four hours post-transfection, the cells were infected
with JEV strain SA 14-14-2 at a MOI of 0.1. (A) Comparison of the number of viral RNA copies at 24 h post-infection among the transfected cells. Data
represent the average values from triplicate experiments. (B) Western blot analysis of gene suppression at the protein level at 24 h post-infection. E
protein was detected as the target and Actin was detected as the internal control. The relative quantities of E protein compared with the mock
control from lane PrM-54 to lane siRNAs69 were 38.7%, 29.2%, 45.2%, 43.8%, 44.1%, 46.6%, 42.4%, 37.5%, 39.0%, 32.9%, 33.7% and 31.9%.
doi:10.1371/journal.pone.0026304.g004
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mismatches with their cognate siRNAs, were synthesized and
cloned into the siQuant vector (Table 2), using the Dual-Luciferase
siRNA-to-target reporter assay system. Then, the inhibitory
efficacy of siRNAs69 on the mutated target sequences was
examined. Compared with the inhibitory efficacy of siRNAs69o n
perfectly complementary target sequences shown in Table 2, the
inhibitory efficacy of siRNAs69 on mutated target sequences was
attenuated to various degrees, depending on the nucleotide
mismatches within the target regions. The inhibitory efficacy
was governed by the position and the quantity of the mismatched
base pairs. When single nucleotide mismatches occurred near the
59 or 39 ends of the target sequences, siRNAs69 could also inhibit
the expression of the target. However, when the nucleotide
mismatches occurred in the middle of the target sequences or
multiple nucleotide mismatches occurred simultaneously, the
inhibitory effect of siRNAs69 was significantly reduced or even
eliminated (Table 2). In general, the inhibitory efficacy shown for
the mutated target sequences of genotypes II and IV indicated that
siRNAs69 could theoretically inhibit the replication of JEV
genotypes II and IV.
Discussion
JEV is classified into four genotypes depending on the
nucleotide sequence of its genomic RNA, with a fifth genotype
being postulated. Genotype III was the first genotype to be
described, and is the most widely distributed [10], followed by
genotype I, which is also an epidemic genotype of JEV. Genotypes
I and III are the predominant genotypes in the mainland of China
[11]. Genotypes II and IV are endemic genotypes. Strain Muar,
isolated in 1952, may represent the fifth genotype [10]. Previous
anti-JEV studies focused on genotype III of JEV and showed that
siRNA-induced gene silence could inhibit efficiently the replication
of one JEV strain of genotype III (Nakayama strain, or SA 14-14-2
strain) in cultured cells [3,25,27]. However, these effective siRNAs
have only been confirmed in one strain of genotype III and may
not be suitable for other strains because of the nucleotide sequence
Figure 5. Inhibitory effects on JEV strain SA 14-14-2 replication by stable cell lines constitutively expressing siRNAs. Stable cell lines
were seeded in 24-well or 96-well plates and were infected with JEV strain SA 14-14-2 at a MOI of 0.1 when the cell monolayer reached 90–100%
confluence. (A) Comparison of the number of viral RNA copies at 24 h post-infection. (B) Western blot analysis of gene suppression at the protein
level at 36 h post-infection, E protein was detected as the target and Actin was detected as the internal control. (C) Comparison of the viral titers in
culture supernatants at 48 h post-infection. (D) Comparison of cell viability using the MTS assay at 96 h post-infection.
doi:10.1371/journal.pone.0026304.g005
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siRNAs confirmed in genotype III could not provide sufficient
protection from infection by other JEV genotypes because of the
higher genetic variability between the four (or possibly five)
genotypes of JEV [1,4,8,9,10,11]. In addition, one or two siRNAs
are not sufficient to prevent RNAi-resistant escape mutants of this
virus [28,36].
Previous studies showed that using siRNA expression vectors
based on miR-30, miR-155, miR-106b or miR-17-92, could
achieve RNA interference of multiple genes [22,29,30,31,32,33].
In these studies, the regions of pri-miRNAs corresponding to
mature miRNAs were replaced with heterologous stems to express
siRNAs without compromising their silencing activity. Just like
most miRNAs that are transcribed from polycistronic pri-
miRNAs, a reconstructed vector could also express two or more
different siRNAs from a single transcript for effective inhibition of
two or more different target mRNAs. This platform has been
applied successfully in anti-HIV research to prevent the escape
mutants of persistent HIV infection [22,29].
In this study, considering the molecular epidemiological
characteristics and the geographic distribution of the four
genotypes of JEV, the 13 selected siRNA targets were highly
conserved in genotypes I and III and reasonably well conserved in
genotypes II and IV. In theory, these siRNAs would be effective
against all four genotypes of JEV. These 13 siRNAs were
constructed into the pcDNA 6.2–GW/EmGFP-miR vector based
on the miR-155 backbone. The nine siRNAs found to inhibit the
expression of their corresponding targets by greater than 80% in
the Dual-Luciferase assay system, were selected, and their
inhibitory effects on JEV replication were tested. The inhibitory
effects of various combinations of multiple siRNAs from single
polycistrons were also tested. Our miRNA-like polycistron
constructs containing four, five or nine different siRNAs showed
good inhibitory effects on the expression of each target, and the
efficacy of some siRNAs were even increased when chained into
polycistrons, compared with the vectors expressing single siRNAs.
This is the first study to describe the application of long chain
miRNA-like polycistrons (with up to nine different siRNAs)
without significantly compromising silencing activity. miRNA-like
polycistron constructs containing three, six and nine copies of the
same siRNA cassette showed no significant changes in silencing
activity. As the number of copies of NS1-447 increased from 1 to
3, 6 and 9, the expression of its target decreased from 7.1% to
4.3%, 4.0% and 4.2%, respectively. This indicated that the
appropriate number of siRNA copies would provide maximum
silencing activity, and that there is no need to increase persistently
the copy number of siRNAs. This finding differed from that of a
previous study in which, using the miR-155 backbone, inhibition
of the reporter increased along with the number of siRNA copies,
from 2 to 4 to 8 [30]. Another related study showed that, although
each addition of siRNA to the transcript resulted in an increase of
the total amount of mature siRNA generated, the addition of
siRNA copies did not increase significantly the inhibitory efficacy
[37]. These differences may be the result of the different lengths of
the vectors, the different types of processing of each siRNA and the
different saturated concentrations of siRNAs.
Because of the importance of genotype III in China, and in Asia
as a whole, JEV genotype III strain SA 14-14-2 was used first to
test the inhibitory effects of siRNAs. Judging by the inhibitory
effect of the viral RNA and E protein 24 h post-infection, the
transient transfection of each siRNA-encoding vector and
miRNA-like polycistron construct could inhibit the replication of
strain SA 14-14-2 to a certain extent. Low transfection efficiency
may greatly limit the anti-JEV effects of siRNAs. To minimize the
negative impact of low transfection efficiency, we constructed four
stable cell lines constructively expressing three representative
Figure 6. Comparison of the inhibitory effects of miRNA-like polycistrons on JEV genotype I and III strains. Stable cell lines or normal
BHK-21 cells seeded in 24-well or 96-well plates were infected with JEV strain SA14, SH53 or SH101 at a MOI of 0.1. (A) Western blot analysis of E
protein expression of strain SA14 at 36 h post-infection. (B) Western blot analysis of E protein expression of strain SH53 at 36 h post-infection. (C)
Western blot analysis of E protein expression of strain SH101 at 36 h post-infection. (D) Comparison of viral titers in the culture supernatants at 48 h
post-infection. (E) Comparison of cell viability using the MTS assay at 96 h post-infection.
doi:10.1371/journal.pone.0026304.g006
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effects. From the results of viral RNA and E protein analyses, viral
titers and cell viability assays, we confirmed that the selected
siRNAs could effectively inhibit the replication of strain SA 14-14-
2. A single siRNA, NS1-447, provided effective inhibition.
Multimerization of NS1-447 up to six copies maximized the
inhibitory effect. siRNAs69 was less effective than (NS1-447)66,
because all other eight siRNAs were less effective than NS1-447.
Although less effective than (NS1-447)66, multimerization of nine
different siRNAs in a single transcript also increased significantly
the inhibitory effect compared with a single copy of NS1-447.
These results indicated that the single siRNA-encoding vectors
and miRNA-like polycistron constructs selected in the Dual-
Luciferase siRNA-to-target reporter assay system could inhibit
significantly the replication of JEV strain SA 14-14-2, provided the
delivery efficiency of siRNA-encoding vectors was sufficiently high.
Indeed, delivery of siRNA is one of the most challenging problems
in the application of RNAi in modern medicine. Many local and
systemic delivery methods for siRNAs or siRNA-encoding
plasmids, such as lipid-based delivery, viral vector-based delivery,
cell-penetrating peptide-based delivery, and poly (lactic-co-glycolic
acid) (PLGA) nanoparticle-based delivery have been reported in
the past few years [26,38,39,40,41], but there is no generalized
delivery approach for RNAi, with different disease targets
requiring different delivery strategies. For JEV, a rabies virus
glycoprotein (RVG) has been used successfully to specifically
deliver anti-JEV siRNAs into neuronal cells across the blood-brain
barrier [26]. Despite various efforts, further work should be
conducted in vivo to investigate the most appropriate siRNA
delivery strategies.
The applicability of (NS1-447)66 and siRNAs69 in the
inhibition of JEV genotypes I and III was validated by testing
three wild type strains of genotypes I and III, SH53, SH101, and
SA14. Both of the miRNA-like polycistron constructs could
significantly inhibit the replication of the three JEV strains, with
(NS1-447)66 being slightly more effective than siRNAs69. This
result indicated that (NS1-447)66 and siRNAs69 have potential
applicability in treating acute viral encephalitis caused by
genotypes I and III of JEV. Divergence and genetic variability
within the two genotypes could be tolerated by the two miRNA-
like polycistrons. Considering the fact that RNAi-resistant escape
mutants within target regions may be generated following siRNA
treatment [36], (NS1-447)66 may be less effective than
siRNAs69, since it only has a single target. siRNAs69 may
therefore be more suitable for broad-spectrum therapy, alleviating
the negative impact of escape mutants.
Table 2. Schematic representations of the nucleotide differences in the target sequences between genotypes II and IV and the
targets we selected.
Target types Target sequences (all sequence from 59 to 39) Remaining reporter activities (compared with the mock control)
PrM-54 target CATTGCAGACGTTATCGTGAT 16.8%
Genotype II ---C--G-----C--A--T-- 97.8%
Genotype IV ---C--G--T--C-------- 96.3%
NS1-447 target TTGGAACAGCATGCAAATCGA 8.3%
Genotype II C-------------------- 19.7%
Genotype IV C--------T--------T-- 95.2%
NS1-630 target GAAACTTGAGAGGGCAGTCTT 28.3%
Genotype II ---------------T--T-- 72.0%
Genotype IV ---G-----------C----- 90.8%
NS1-1207 target TACACTGATTTGGCGAGGTAT 59.3%
Genotype II -----------------A--- 68.0%
Genotype IV ---------C----------C 98.8%
NS2A-461 target GACTAATGGTCTGCAACCCAA 4.7%
Genotype II ---------C---------G- 88.6%
Genotype IV ----C---------------- 38.6%
NS2B-123 target GTCCTACGTGGTGTCAGGAAA 5.1%
Genotype II ---T----------------- 37.9%
Genotype IV ---T----------------- 37.9%
NS3-1112 target AGATTGCAATGTGCCTCCAAA 34.5%
Genotype II -------------------G- 79.5%
Genotype IV -A-----TG-T--------G- 100.0%
NS4A-289 target GCAGAGGTTCCTGGAACCAAA 11.0%
Genotype II -----------C-----T--- 100.0%
Genotype IV -----A--GT-A--------G 91.2%
NS4B-115 target ACTGATGTGCCTGAACTGGAA 11.3%
Genotype II -----------A--------- 98.6%
Genotype IV --------------------- 11.3%
The inhibitory efficacies of siRNAs69 on each target were estimated using the Dual-Luciferase siRNA-to-target reporter assay system.
doi:10.1371/journal.pone.0026304.t002
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unavailable to validate the applicability of the two miRNA-like
polycistrons in this study, because these two genotypes are rare in
mainland China. However, we designed an alternative method to
validate the inhibitory effects of the two miRNA-like polycis-
trons on genotype II and IV strains. After analyzing the genome
sequences of genotypes II and IV available in the GenBank
database, the target sequences of genotypes II and IV which
contain mutations were synthesized and cloned into the reporter
plasmid, siQuant. The inhibitory effects of siRNAs69 on each
mutated target were then estimated (Table 2), and the inhibitory
effect of (NS1-447)66 on the mutated targets of NS1-447 were
estimated (data not shown). In agreement with previous studies
[42,43], we found that perfect matches in the central region of the
target is critical for the effective inhibition of RNAi, and single
mismatches occurring in the central region could eliminate
the inhibitory effect of RNAi. In addition, multiple nucleotide
mismatches in one target could eliminate the inhibitory effect of
siRNA. Conversely, single mismatches occurring near the 59 or 39
ends of the target sequence could be well tolerated. In summary,
the position and quantity of mismatches between the target
sequence and the cognate siRNA affect the efficiency of inhibition.
Although mutated nucleotides could attenuate the inhibitory effect
of siRNAs69 to varying degrees, the effect of extending the siRNA
chain to siRNAs69 could be complementary in preventing the
inefficacy of two or three pre-designed siRNAs. Furthermore, the
copy number (or proportion) of each siRNA in the chain could be
adjusted according to the genotype of target JEV strain to achieve
maximal inhibitory effect. This reporter system demonstrated, in
theory, the inhibitory effect of siRNAs69 on genotype II and IV
strains of JEV. (NS1-447)66 would also be effective at inhibiting
genotype II strains because single mutated nucleotides at the 59
end of the target would not affect the efficiency of RNAi.
In contrast, (NS1-447)66 would not be suitable for inhibiting
genotype IV strains, because single mutated nucleotides in the
centre of the target would completely eliminate silencing activity.
In conclusion, the results of this study offer the possibility of
inhibiting the replication of JEV strains of the four genotypes using
a single miRNA polycistron containing multiple siRNAs. The
strong, broad-spectrum, anti-JEV activity of the miRNA poly-
cistron could be applied to the development of effective antiviral
gene therapies.
Materials and Methods
Cell cultures and virus assays
Baby hamster kidney cell line (BHK-21; ATCC, USA) cells were
propagated andmaintainedinDulbecco’smodifiedEagle’smedium
(DMEM; Gibco, Invitrogen, USA) supplemented with 10% fetal
bovineserum(FBS;Gibco,Invitrogen,USA)at37uCwith5%CO2.
The JEV strains SA 14-14-2, SA 14, SH101 and SH53 were
provided by Dr. Yongxin Yu, Department of First Viral Vaccine,
National Institute for the Control of Pharmaceutical and
Biological Products. Strains SA 14-14-2 and SA 14 belong to
genotype III. Strains SH101 and SH53 belong to genotype I. All
viruses were propagated in BHK-21 cells. The 50% tissue culture
infective dose (TCID50) was calculated in BHK-21 cells using 96-
well plates and the Reed-Muench formula [44].
Plasmid construction
For siRNA-encoding plasmids, the highly conserved regions of
eight genes (PrM, NS1, NS2A, NS2B, NS3, NS4A, NS4B and
NS5) among the four genotypes of JEV were determined by
sequence alignment using the SeqMan program available within
the Lasergene 7 package (DNAStar, USA). Thirteen siRNAs
based on these conserved regions (Figure 1 and Table 1) were
designed using the miRNA design algorithm (http://rnaidesigner.
invitrogen.com/rnaiexpress/setOption.do?designOption=mirna&
pid=509133211138749536). These 13 siRNAs were individually
cloned into pcDNA 6.2–GW/EmGFP-miR (Invitrogen, USA), a
RNA polymerase II-driven siRNA expression vector based on the
miR-155 backbone, according to the manufacturer’s recommen-
dations (the sequences of hairpin siRNA inserts were shown in
Table S1). Combination of multiple siRNAs cassettes from a single
miRNA-like polycistron construct was performed by digesting a
single siRNA hairpin unit with BamHI and XhoI and inserting the
digested fragment into the BglII/XhoI sites of pcDNA 6.2–GW/
EmGFP-miR. We obtained different combinations of multiple
siRNAs by repeating this procedure. We simultaneously designed a
negative control (NC), which comprised scrambled siRNA
containing the same nucleotide component as PrM-54. Every
clone was verified by PCR and sequencing.
To construct the reporter vector, the target sequences of these
13 siRNAs (Table 1) were cloned into the BglII/ApaI sites of the
siQuant vector (Genordia AB, Sweden), as described previously, to
fuse the target sequences to the firefly luciferase gene [45].
siRNA efficacy validation
BHK-21 cells were plated in 24-well plates (0.5 ml medium/
well) and cultured at 37uC with 5% CO2 for 24 h. When the cell
layer reached 60–70% confluence, siRNA-encoding pcDNA 6.2–
GW/EmGFP-miR vectors (400 ng), as well as the reporter
plasmids (170 ng of target-encoding siQuant vectors and 17 ng
of pRL-TK as an internal control) were co-transfected using
Lipofectamine 2000 (Invitrogen, USA) according to the manufac-
turer’s recommendations. Forty-eight hours post-transfection, cells
were harvested and the firefly luciferase and Renilla luciferase
activities were measured on SpectraMax M5 (Molecular Devices,
USA) using the Dual-Luciferase Reporter Assay System (Promega,
USA). The inhibitory effects generated by the siRNA-eocoding
pcDNA 6.2–GW/EmGFP-miR vectors were expressed as nor-
malized ratios between the reporter and control luciferase
activities [31,42,45].
Transfection and virus infection
BHK-21 cells were seeded in 24-well plates. When the cell layer
reached 60–70% confluence, each siRNA-encoding pcDNA 6.2–
GW/EmGFP-miR vector (800 ng) was transiently transfected into
the cells. Twenty-four hours post-transfection, the cells were
infected with JEV strain SA 14-14-2 at a multiplicity of infection
(MOI) of 0.1. After 1–2 h adsorption, the inocula were removed
and cells were incubated in DMEM supplemented with 10% FBS.
Real-time reverse transcription (RT)-PCR
The following primers: forward, 59-CCTCCGTCACCATGC-
CAGTCTTAG-39 and reverse, 59-TTCGCCATGGTCTTT-
TTCCTCTCG-39, were used to amplify the region spanning nt
3976–4108 in the genome of JEV strain SA 14-14-2. This region
was then cloned into the pGEM-T Easy Vector (Promega, USA)
to construct the standard plasmid. Using the standard plasmid we
obtained a standard curve.
The RNAeasy Mini kit (Qiagen, Germany) was used for RNA
extraction from every well 24 h post-infection according to the
manufacturer’s instructions. A reverse transcription (RT) reaction
was carried out using Superscript III Reverse Transcriptase
(Invitrogen, USA) in a 20 ml reaction mixture with 1.2 mg of total
RNA. Real-time PCR was conducted using an ABI Prism 7000
Real-time PCR system (Applied Biosystems, USA). Reactions were
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each primer and 25 ml of Power SYBR Green PCR Master Mix
(Applied Biosystems, USA). Viral RNA was quantified using the
standard curve.
SDS-PAGE and Western blot analysis
BHK-21 cells at 24 h or 36 h post-infection were washed twice
with PBS and lysed with 100 ml M-PER mammalian protein
extraction reagent (Pierce, USA). Then, 20 ml lysates were boiled
for 5–10 min after mixed with 56loading buffer. Proteins were
separated by 12% sodium dodecylsulfate polyacrylamide gel
electropheresis (SDS-PAGE) and transferred to nitrocellulose
membrane (Bio-Rad, USA) using a semi-dry electrophoretic cell
(Bio-Rad, USA). For immunoblotting, membranes were first
incubated with mouse anti-JEV E-D3 monoclonal antibody
(Beijing Protein Innovation, China) at a dilution of 1:2000 or
mouse anti-actin monoclonal antibody (Sigma, USA) at a dilution
of 1:5000. Membranes were then incubated with IRDye 680
conjugated goat anti-mouse secondary antibody (Li-Cor Biosci-
ences, USA) at a dilution of 1:5000 or 1:15000. Protein bands
were detected and quantified using the Li-Cor Odyssey system
and the Odyssey infrared imaging software (Li-Cor Biosciences,
USA).
Flow cytometry assay
At 48 h post-transfection, the siRNA-encoding pcDNA 6.2–
GW/EmGFP-miR transfected cells and the control cells were
washed twice with PBS, trypsinized and resuspended in PBS.
EmGFP positive cells were evaluated by flow cytometry using a
FACSCanto II flow cytometer (BD Bioscience, USA).
Establishment of stable cell lines constitutively
expressing siRNAs
BHK-21 cells were seeded in 24-well plates. When the cell layer
reached 50% confluence, the selected siRNA-encoding pcDNA
6.2–GW/EmGFP-miR vector (400 ng) was transiently transfected
into cells. Twenty-four hours post-transfection, cells cultured in
DMEM containing 4 mg/ml blasticidin were trypsinized and
replated into 10 cm tissue culture plates. The medium was
replaced with fresh DMEM containing blasticidin (4 mg/ml) every
3–4 days until blasticidin-resistant colonies were obtained.
Individual colonies were obtained by serial dilution and were
screened by cell viability assays following JEV infection.
Established clones that could maximally inhibit the propagation
of virus were propagated and maintained in DMEM containing
2 mg/ml blasticidin.
Cell viability assay
BHK-21 cells constitutively expressing siRNAs or control cells
were seeded in 96-well plates for 24 h and then infected with JEV
at a MOI of 0.1. Ninety-six hours post-infection, 20 ml MTS/PMS
(Promega, USA) was added to each well and the absorbance at
490 nm was measured according to the manufacturer’s recom-
mendations.
Statistical analysis
All experiments were repeated at least thrice, and standard
deviation of the mean was determined. Statistical analyses were
performed by paired t-test using Statistical Product and Service
Solutions (SPSS, USA).
Supporting Information
Figure S1 Flow cytometryanalysis of the transfectionef-
ficiency of the siRNA-encoding vector. Cells seeded in 24-
well plates were transfectedwith 800 ngof single siRNAs. Twenty-
four hours post-transfection, the cells were infected with JEV
strain SA 14-14-2 at a MOI of 0.1. At 48 h post-transfection,
EmGFPpositive cells were evaluated by flow cytometry. Control-
P1, non-transfectedBHK-21 cells; Sample-P1, single siRNA-
encoding pcDNA6.2–GW/EmGFP-miRtransfectedBHK-21 cells.
(TIF)
Figure S2 Inhibitory effects on JEV strain SA 14-14-2
replication by stable cell lines constitutively expressing
siRNAs. Stable cell lines were seeded in 24-well or 96-well plates
and were infected with JEV strain SA 14-14-2 at a MOI of 0.1
when the cell layer reached 90–100% confluence. Morphological
changes in the stable cell lines or normal BHK-21 cells at 96 h
post-infection.
(TIF)
Table S1 The sequences of hairpin siRNA inserts of
pcDNA 6.2–GW/EmGFP-miR.
(DOC)
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